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ABSTRACT  
Objective: Fatigue is frequently reported by patients with inflammatory bowel 
disease (IBD), irrespective of disease activity; however, evidence regarding fatigue 
management is limited. This study tested the effect of individualised advice to 
increase physical activity and/or omega-3 fatty acids supplementation, on IBD-related 
fatigue.  
Methods: A pilot study in patients with inactive IBD, utilising a randomised controlled 
2x2 factorial design (four groups) compared baseline and post-intervention fatigue 
scores. Study interventions: individualised exercise advice (15 minute consultation) 
and/or supplementation (omega-3 fatty acids, 2970mg/day) for 12 weeks. Control 
interventions: general health discussion and/or placebo supplement. All patients 
received follow-up support. Primary outcome was fatigue measured by Functional 
Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale score; secondary 
outcomes included change in Inflammatory Bowel Disease-Fatigue (IBD-F) scale score. 
Results: From n=656 screened patients, n=74 who met the selection criteria  were 
randomised, n=60 commenced,  and n=52 completed the study. tThe primary 
outcome fatigue, measured with FACIT-F, showed slight worsening  in the omega-3 
supplementation group (95%CI:-8.6-(-0.7);p=0.02), and no change in the exercise 
advice group (p=0.38). Reduced fatigue, measured by IBD-F score, was identified in 
the exercise group (95%CI:-3.8-(-0.2);p=0.03). One treatment-related adverse event 
(musculoskeletal pain) was reported with exercise. 
Conclusions: Advice to increase physical activity and omega-3 supplementation, singly 
or in combination, were shown to be safe and generally well-tolerated. There was no 
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evidence of exercise-related adverse effects on gut-related symptoms, and some 
evidence of improvement in fatigue. The slight worsening of fatigue with omega-3 
supplementation is unexplained. Regular moderate to vigorous exercise may be a self-
management option in IBD-related fatigue. 
Keywords: IBD-Fatigue; Nutrition; Omega-3 supplementation; Physical Activity. 
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INTRODUCTION 
Fatigue is predominantly a feature of active inflammatory bowel disease (IBD), but 
remains a problem for some patients even during remission, with a prevalence of 41-
48%(1). With negative impact on health-related quality of life (HRQOL)(2), fatigue is 
consistently reported as a major concern for IBD patients (3, 4). Several physical and 
psychological factors, such as disease activity and depression, have been reported to 
influence fatigue in IBD, although inconsistencies in these reports prevent firm 
conclusions being drawn(1, 5). Results from randomised controlled trials (RCTs) on 
IBD-related fatigue have reported reductions of fatigue with infliximab or 
adalimumab(6-8), and benefits from a stress management programme(9) and 
solution-focused therapy(10). However, few studies identify fatigue as their primary 
endpoint(11), and there is no consensus regarding mechanisms driving fatigue or 
suggestions for treatment. 
Fatigue appears in diseases involving the immune system, e.g. cancer, rheumatoid 
arthritis (RA), and multiple sclerosis (MS). Recent evidence suggests similarities in 
fatigue between  different conditions(12, 13), though it is unclear which elements of 
fatigue co-exist.  Although physical activity (PA) has been suggested to be appropriate 
for adults and children with IBD(14, 15), patients may raise concerns regarding 
exercise-related exacerbation of their symptoms(21). There are no evidence-based 
guidelines or recommendations regarding type, duration and intensity of exercise for 
IBD patients(16). A few small cohort studies testing PA in IBD patients have reported 
exercise to be well-tolerated(17-20). Patients with Crohn’s Disease (CD) tolerated 
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cycling at low (60%) oxygen consumption(17). (18). Need to say what this means – ie 
low O2 consumption means physiologically well tolerated 
Improvements in HRQOL and psychological benefits were reported in CD patients 
(with no/mild-moderate disease activity) undergoing low to moderate intensity PA 
programmes insert 18, 20, 22 (19, 21, 22). Greater impairments in physical fitness 
(assessed by cardiorespiratory fitness, 6-minute walk distance, and isokinetic muscle 
strength) and PA levels were reported in fatigued compared with non-fatigued IBD 
patients, and these were ameliorated by exercise(23). Self-reported fatigue and 
skeletal muscle fatigue were significantly correlated in CD patients and non-IBD 
controls (24). It has been suggested that anti-inflammatory peptides released by 
exercising muscle could reduce muscle fatigue(25). This mechanism may have 
potential for reducing IBD-related fatigue.  
Exercise interventions have been tested for fatigue management in other chronic 
disorders. A Cochrane review of the effects of exercise on fatigue in patients with 
advanced progressive illnesses, such as cancer and MS, reported a benefit from 
exercise (26). However, review of studies in RA reported only limited benefit from 
exercise on fatigue (27). 
Several characteristics of omega-3 fatty acids (ω-3 FAs, also known as omega-3 fish 
oils) suggest a potential beneficial role in the management of IBD-related fatigue, 
with positive effects on muscle strength and/or reduced muscle fatigue (32), 
decreased inflammation and improved mood(28). Eicosapentaenoic acid (EPA)  was 
reported to be particularly beneficial for treating mild depression(29), suggesting that 
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ω-3 FAs might improve mood and HRQOL in IBD patients through the release of 
cytokines, neuropeptides and eicosanoids in the gut, hence influencing brain 
function(30, 31). (32).  
A study of breast cancer survivors reported that higher intake of ω-3 FAs was 
significantly associated with reduced physical parameters of fatigue(33).  In advanced 
lung cancer, supplementation with ω-3 FAs (amongst other treatments) reduced 
fatigue and inflammation significantly(34). However neither study measured cancer-
related fatigue as the primary endpoint. Systematic reviews of the effect of ω-3 FAs 
on the maintenance of IBD remission have found insufficient evidence to recommend 
a change in clinical practice(35-37), although further interventional studies were 
recommended. Many previous studies have used IBD populations with mixed disease 
activity, precluding generalisation of results to patients either with active disease or 
those in remission. Studies in participants with defined disease activity may provide 
greater clarity regarding effects of interventions. 
Therefore, this pilot RCT aimed to test the safety and effectiveness of two 
interventions (i) individual advice to increase PA and/or (ii) supplementation with ω-3 
FAs, on fatigue in patients with inactive IBD. 
METHODS  
A pilot RCT with a 2x2 factorial design was used to test the effect of PA and/or ω-3 
FAs on fatigue. The active interventions consisted of: i) Personalised exercise advice 
to increase PA by 30% and ii) Oral ω-3 FAs capsule supplementation. Participants 
were randomised to one of four groups (See Table 1): 
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1) Exercise advice with ω-3 FAs supplement capsule 
2) Exercise advice with placebo capsule  
3) ω-3 FAs supplement capsule with exercise placebo  
4) Placebo capsule with exercise placebo  
Researchers were blinded to capsule type, but not to consultation type; participants 
were blinded to capsule type and objective PA accelerometer readout, but not to 
their own level of PA. Block randomisation with computer-generated random 
numbers allotted participants to one of the four study groups, ensuring similar 
characteristics and number of participants per group. A schedule of three visits, 
baseline measures, initiation and completion of the intervention, were required for 
participation in the study (see Figure 1 and Supplementary Data, Methods).  All 
patients received follow-up support via email or telephone. The study was approved 
by the Dulwich Research Ethics Committee (REC 12/LO/1856; ). All data were coded 
prior to analysis to ensure participants’ confidentiality and anonymity.  
Study Participants 
Prospective study participants were approached at tertiary referral hospital IBD out-
patient clinics. Those willing to participate were recruited if they met the eligibility 
criteria of: clinically confirmed CD or UC in remission [C-reactive protein (CRP) 
<5mg/dl; Harvey-Bradshaw Index (HBI) <5 (38) or Simple Clinical Colitis Index (SCCI) 
<3 (39)]; self-diagnosed fatigue; ≥18 years old; willing to increase their current activity 
levels; and able to take medication with ingredients derived from animal/fish sources.  
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Patients were excluded if they had any of the confounding comorbidities: anaemia, 
depression, MS???, unstable respiratory or cardiovascular disease, uncontrolled 
hypertension, mental illness, cognitive dysfunction, reduced mobility,   Chronic 
Fatigue Syndrome or Myalgic Encephalopathy. Patients were also excluded if they 
were currently pregnant, taking anticoagulant medications, consumed oily fish ≥ twice 
per week or 8 times per month, took ω-3 FA supplements during the 12 weeks before 
screening, performed ≥60 minutes of moderate-vigorous exercise weekly, or were 
currently participating in another RCT.  
Description of interventions 
Interventions were delivered over a 12 week period  
i) Exercise Advice: An individual 15-minute consultation with a personal trainer and 
researcher (AM) was provided at week 1. Advice consisted of individualised goal 
setting using the treatment paradigm of ‘Treat-to-Target’(40) to initiate a ≥30% 
increase in PA levels. This is in line with current recommendations of 30-60 min of 
dynamic exercise of the large muscles, three to four times per week (41). Personal PA 
goals and achievements were recorded in a diary kept by participants for the study 
duration.  A positive approach to the PA advice provided was encouraged by initiating 
and maintaining motivation. This utilised techniques of imagery, goal setting (for each 
week and the whole programme), and overcoming barriers to exercise (e.g. physical 
limitations and fears of worsening IBD symptoms). The exercise trainer assessed 
participants’ mobility, and from their self-reported clinical and exercise history 
(frequency, duration and intensity of exercise), suggested a type of activity enabling 
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an increase in exercise levels. Examples of PA for less active individuals included 
initiation of walking, swimming and simple gym routines. For those already 
undertaking some exercise, the trainer suggested activities enabling them to extend 
their personal goals e.g. training for a 5km - 10km run.  
ii) ω-3 FAs Supplement Capsules: A total daily oral dose comprised 2970mg ω-3 FAs 
(EPA, 2250mg; DHA, 150mg; “Take Omega-3”©, Edinburgh, UK) in three capsules. 
Current guidelines suggest that doses up to 3g per day of marine derived ω-3 FAs are 
safe (42); a high EPA:DHA ratio is thought to be preferable (29, 43, 44).   
iii) Exercise Placebo: A 15-minute conversation with the researcher (AM) about the 
participant’s’ current dietary habits and general health was undertaken at week 1, 
including questions such as: ‘Can you tell me about your current diet?’, ‘Did you have 
to change your diet following the diagnosis of IBD?’, and ‘In what way has IBD 
affected your general health?’ No advice was given by the researcher regarding a 
healthy lifestyle.  
iv) Capsule Placebo: Similar appearing capsules to the ω-3 FAs supplement capsules 
contained placebo (capric and caprylic acid).  
Participants in all groups were contacted by the researcher (AM) via telephone or 
email on six occasions during the intervention, a week following commencement of 
the interventions and then approximately every two weeks. Topics of conversation, 
specific to the participants’ group allocation, covered their well-being, whether they 
were taking the capsules as instructed, and the occurrence of any adverse effects. In 
addition, those receiving exercise advice were asked about progress towards set goals 
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during that period. The exercise goals were reinforced and renegotiated (if 
necessary), and any adverse effects or barriers to activity were discussed. Participants 
were also reminded not to eat ≥2 portions of oily fish/week or 8 portions per month, 
and not to take additional ω-3 FA supplements during the intervention period. 
Compliance to ω-3 FA supplement intake was assessed via self-report diary, kept by 
all study participants, in which they recorded their capsule intake, levels of dietary 
sources of ω-3 FAs, and possible treatment-related adverse effects. Participants 
returned left-over capsules, which were counted to assess the number of capsules 
missed. Compliance to increased exercise during the intervention period was assessed 
by comparison of goals set and achievements recorded in the self-report diaries.  
Study Outcomes and Measurement Tools 
The primary study outcome was fatigue, measured with the Functional Assessment of 
Chronic Illness Therapy – Fatigue scale (FACIT-F)(45). Other fatigue scales were used 
as secondary outcome measures: the Multidimensional Fatigue Inventory (MFI)(46) 
and the Inflammatory Bowel Disease-Fatigue (IBD-F) scale (47). In addition, HRQOL 
was assessed with the Inflammatory Bowel Disease Quality of Life questionnaire 
(IBDQ)(48), and anxiety and depression with the Hospital Anxiety and Depression 
Scale (HADS)(49). Physical activity levels were recorded daily for up to seven non-
contiguous days (incorporating two weekend days and at least four weekdays), using 
a bi-axial accelerometer GT1M (Actigraph, Pensacola, US)(50). A valid PA assessment 
was defined as wear-time ≥11 hours per day, and data were analysed using Actilife 
data analysis software version 6.5. All outcomes were assessed at baseline and at the 
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end of the treatment. Participants’ demographic data and other variables (see Table 
2) were also collected. 
Statistical Methods 
Categorical variables were analysed with Fisher's exact test. Continuous variables 
found to be normally distributed were analysed using analysis of variance (ANOVA), 
whilst continuous variables not found to be normally distributed were analysed using 
the Kruskal-Wallis test.  
Continuous outcomes were analysed using analysis of covariance (ANCOVA). Non-
normally distributed data  were analysed on a log scale. Binary outcomes were 
analysed by logistic regression. The baseline value of each outcome was used as a 
covariate in the analysis. A p-value ≤0.01 was deemed statistically significant for all 
outcomes since multiple measurements were collected. 
RESULTS  
Study Participants 
Recruitment took place over a period of 13 months, and 656 patients were screened. 
Those eligible for the study received the Patient Information Sheet before informed 
consent was obtained. Seventy-four participants were randomised,  60 commenced 
the intervention and 52 completed the protocol. Study flow and reasons for 
withdrawal and exclusion of patients are shown in Figure 2. Data were analysed on an 
intention-to-treat basis; however, results did not differ from those following per 
protocol analysis. 
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Baseline variables 
Baseline values of variables in the four study groups were comparable in relation to 
disease type, location, activity scores, treatment received (Table 3), and fatigue scale 
scores and PA (Supplementary data, Table S1). The only difference between groups at 
baseline was for depression (p=0.04), highest in the group receiving ω-3 FAs and 
exercise placebo, which was adjusted for in subsequent analyses. 
Outcome variables 
There were no interactions (at p-value <0.01) between the effects of exercise advice 
and those of ω-3 FAs on fatigue (Table 4), enabling analysis as two rather than four 
groups. Hence, data from all patients was used to evaluate both interventions: for 
exercise advice (n=26) versus exercise placebo (n=26); and for ω-3 FA supplement 
(n=25) versus placebo supplement (n=27), adjusted for the baseline difference in 
depression between groups (Table 1).  
There was no significant difference in fatigue measured by FACIT-F score between 
those receiving exercise advice and exercise placebo (p=0.38). However, a small but 
not statistically significant difference was shown between mean FACIT-F scores for 
those receiving the ω-3 FA supplement compared to those receiving placebo capsules 
(mean (95% CI): -4.6 (-8.6, -0.7);p=0.02).  Patients receiving ω-3 FA supplements had 
average scores 4.6 units lower (worse fatigue) than patients receiving placebo.  
Fatigue severity, measured by the IBD-F scale as a secondary outcome, was lower in 
patients receiving exercise advice than in those receiving exercise placebo (mean 
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(95% CI): -2.0 (-3.8, -0.2); p=0.03). However, there was no observed effect of ω-3 FAs 
on the IBD-F scale scores (Table 4). No statistically significant changes for any of the 
other secondary outcomes (disease activity scores, other fatigue scale scores, and 
anxiety and depression scores) were found between exercise advice, ω-3 FA, or 
placebo groups (at p-value <0.01) (Table 4). 
Satisfactory compliance of all groups to low levels of dietary sources of ω-3 FAs, and 
correct capsule intake were reported (Table 4). Diary entries from the exercise groups 
indicated broad compliance with the goals set, although no changes in PA levels were 
documented following the intervention period (Table 4). 
Adverse events 
Seventeen adverse events were reported, including gastrointestinal, musculoskeletal, 
and dermatological side effects (Figure 3), with no differences between the four 
treatment groups (p=0.51). The Odds Ratios (CI 95%) for a patient experiencing an 
adverse event following receipt of exercise advice or ω-3 FAs were 1.14 (CI 0.35-3.67) 
and 0.67 (CI 0.21-2.18) (p=0.51), respectively. None of the adverse events were 
considered serious, with only one case of musculoskeletal pain (considered as likely to 
have been related to treatment) resulting in cessation of exercise. The most 
frequently reported symptoms, of diarrhoea or epigastric discomfort, both common 
in IBD, were no more apparent in exercisers or those taking ω-3 FAs. No patient 
discontinued the supplements due to adverse effects.  
DISCUSSION 
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This single site, pilot RCT tested the effect of advice to increase exercise, alone or in 
combination with ω-3 FA supplementation, on fatigue in IBD patients.  The 
interventions were shown to be safe and generally well-tolerated.  This is the first 
study in IBD patients providing individually-prescribed advice relating to non-
supervised PA on a Treat-to-Target basis (40), aiming to increase each individual 
participant’s PA by 30%. This approach also promotes engagement in non-supervised 
exercise by previous non-exercisers. Reports from participants receiving the exercise 
advice ranged from expressions of initial enthusiasm to life-changing positive 
experiences. Improvement in fatigue was only demonstrable with the secondary 
outcome measure (IBD-F), and not from the primary measure (FACIT-F). In the ω-3 
FAs group, a slight worsening of fatigue as measured by the FACIT-F scale was not 
statistically significant.   
The effect of ω-3 FAs on fatigue in IBD has not been studied previously. Results from 
RCTs in healthy individuals have shown beneficial effects of ω-3 FA supplementation 
for weeks on cognitive function and mood(43, 44, 51). A 6-week intervention 
including ω-3 FAs significantly reduced fatigue in patients with lung cancer(34), and 
an ongoing randomised trial of ω-3 FAs in breast cancer-related fatigue is also using a 
6-week treatment period (https://clinicaltrials.gov/ct2/show/NCT02352779). In our 
study on IBD patients, a 12-week period of ω-3 FA supplementation, did not show 
positive effects on fatigue, although it is possible that a longer period of 
supplementation may reduce IBD-related fatigue (47, 52).  
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Previous studies using 1800mg-7000mg ω-3 FAs per day (compared to the 2970mg 
daily dose in this study), showed positive effects on remission maintenance in IBD 
patients (1, 35), although beneficial effects on IBD-related fatigue may require 
different dosage regimes.  Omega-3 FA supplementation at lower dose (up to 690mg 
per day) and for a shorter period (8 weeks) than in the present study, significantly 
increased levels of blood erythrocyte ω-3 FAs (53). This further suggests that the 12-
week period in this study should be sufficient to show positive effects on fatigue from 
ω-3 FAs supplementation if such an effect exists. 
There was some indication that exercise advice improved IBD-related fatigue. This 
was demonstrated by lower scores from the IBD-specific fatigue scale, although this 
effect was not apparent from other fatigue scales. Studies investigating the effect of 
exercise on symptoms of chronic disease, including fatigue, have reported on 
intervention periods of 12 weeks or less (26, 27). A recent RCT investigating the effect 
of a 10-week PA program in 30 cases of mild-moderate IBD has reported a non-
significant increase in HRQOL, predominantly through effects on the IBD-Q social 
subscale(22). Thus, larger and possibly longer studies investigating the effect of 
exercise on IBD-related fatigue are needed(22, 54, 55).   
Exercise has proven beneficial in healthy individuals(41). Potential positive benefits 
were also reported in studies with IBD patients, including muscle mass gain(56), and 
increased bone mineral density and HRQOL(21). Symptoms of IBD, such as 
diarrhoea,especially if accompanied by fears of incontinence, may create barriers to 
exercise(57). Evidence to date suggests that individuals with IBD should benefit from 
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increased exercise(15, 23, 24, 58, 59), and in particular, that low-moderate PA is 
safe(19, 60). The results from our study support these findings: no serious adverse 
effects related to exercise were reported. Clinicians’ reluctance to prescribe exercise 
because of the fear of symptom exacerbation can now be largely dispelled(21). 
The strength of this study lies in its 2x2 factorial design; in the absence of interaction 
between the effects of exercise advice and ω-3 FA supplements on IBD-related 
fatigue, data could be analysed with two groups (n=25-27). The relatively small 
sample size may be seen as a limitation, although this can be justified given the trial’s 
pilot status.  Despite the large numbers of patients screened, many were excluded 
because of the stringent eligibility criteria used to remove confounding factors, (e.g. 
fatigue-related comorbidities (131/656 ; 20%), or else because of their non-availability 
(147/656; 23%). A variety of variables were measured; however in the future, 
additional variables including faecal calprotectin, body composition analysis, baseline 
serum levels of vitamin B12 and ferritin, plus post-interventional serum 
concentrations of ω-3 FAs, could be determined to add to the understanding and 
interpretation of the results. Whilst the self-report diaries used in this study may be 
useful tools to confirm adherence to protocols, they have known limitations since 
their veracity cannot be proven. However, careful review of the completed diaries 
suggested contemporaneous completion without systemic consumption bias.   I too 
don’t know what this means 
4.2 Conclusions 
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This was the first study assessing the effect of exercise advice and/or ω-3 FA 
supplementation in IBD patients, and the results demonstrate that these 
interventions are generally well-tolerated. Patients with IBD-related fatigue could 
safely increase levels of PA.  There is a need for further investigation in a larger 
sample to derive recommendations and specific practice-based guidelines. Omega-3 
FA supplementation did not produce positive results on IBD-related fatigue, although 
there were no serious adverse effects related to its intake. It is possible that regular 
moderate-vigorous physical activity may provide a safe and effective self-
management option in IBD-related fatigue.  
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TABLES 
 
 
       Exercise Advice     
  Yes  No  
Omega-3 Fatty 
Acids 
Yes Exercise advice +   
ω-3 FAs (Group 1) 
ω-3 FAs  
(Group 3) 
 
No Exercise advice 
(Group 2) 
Neither  
(Group 4) 
 
Treatment Groups: 
1) Exercise advice with ω-3 FAs supplement capsule (n=11):  
Consultation with personal trainer; activity and diet diary; omega-3 fatty acid 
capusles 
2) Exercise advice with capsule placebo (n=15):  
Consultation with personal trainer; activity and diet diary; capsule placebo  
3) ω-3 FAs supplement capsule with exercise placebo (n=14) 
Consultation with researcher; diet diary; omega-3 fatty acid capusles  
4) Capsule placebo with exercise placebo (n=12) 
Consultation with researcher; diet diary; capsule placebo  
 
Table 1: 2x2 Trial Design and Details of Treatment Groups.   
 
ω-3 FA: Omega-3 Fatty Acids. 
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Outcome variable Scale/Assessment Outcome Rationale 
Fatigue score Functional 
Assessment of 
Chronic Illness 
Therapy – Fatigue 
scale(45) 
Primary  Scale validated  in IBD 
patients by correlation 
with inflammatory 
markers  
Fatigue score Multiple Fatigue 
Inventory 
scale(46) 
Secondary  
 
 
 
Widely-used scale; 
inclusion allows 
comparison with other 
fatigued populations 
Fatigue score Inflammatory 
Bowel Disease- 
Fatigue scale(47) 
Secondary  Newly-developed 
scale, validated for 
use with IBD patients 
Quality of Life 
score 
Inflammatory 
Bowel Disease – 
Quality of Life 
scale(48) 
Secondary  Health-related quality 
of life scale validated 
for use with IBD 
patients 
Depression score Hospital Anxiety 
and Depression 
scale(49) 
Secondary Scale assessing role of 
anxiety and 
depression in 
influencing fatigue 
levels 
Activity counts  
per minute; Time 
spent in 
Moderate-
Vigorous Physical 
Activity;  
Daily steps 
Accelerometer, 
GT1M 
(Actigraph)(50) 
Secondary  Objective measure of 
physical activity 
Disease activity 
score 
Harvey-Bradshaw 
Index(38)  and 
Simple Clinical 
Colitis Index(39) 
Secondary Validated scales 
indicating level of 
disease activity  
Height and weight 
measurement 
Procedure Secondary To indicate change in 
body composition 
Haemoglobin 
measurement 
Procedure - blood 
test 
Secondary To determine iron 
status 
C-Reactive Protein 
measurement 
Procedure  - 
blood test 
Secondary As a marker of 
inflammation 
 
Table 2: Details of Assessment Tools Used for Data Collection. 
IBD: Inflammatory bowel disease 
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Variable Placebo Omega-3 Fish Oils p-value 
 No Exercise 
(n=12) 
Exercise 
(n=15) 
No Exercise 
(n=14) 
Exercise 
(n=11) 
 
      
Age a 31 (27, 51) 35 (28, 43) 45 (36, 51) 31 (29, 55) 0.52 
      
Gender - Male 4 (33%) 8 (53%) 7 (50%) 6 (55%) 0.74 
      
Ethnicity - White 9 (75%) 10 (67%) 14 (100%) 9 (82%) 0.11 
                 - Other 3 (25%) 5 (33%) 0 (0%) 2 (18%)  
      
Smoker - No 11 (92%) 14 (93%) 13 (93%) 9 (82%) 0.80 
      
Haemoglobin b 13.7 (1.7) 13.6 (1.4) 13.5 (0.9) 13.8 (1.4) 0.96 
      
CRP a 1.6 (0.7, 2.7) 1.0 (0.6, 3.3) 1.2 (0.7, 3.2) 2.4 (1.2, 6.2) 0.29 
      
BMI (kg/m2) b 24.9 (4.5) 23.9 (4.2) 25.7 (3.9) 26.3 (3.1) 0.46 
 
Diagnosis - CD 
 
6 (50%) 
 
6 (40%) 
 
7 (50%) 
 
6 (55%) 
 
0.99 
   - UC 6 (50%) 8 (53%) 7 (50%) 5 (45%)  
   - IBD 
unclassified  
0 (0%) 1 (7%) 0 (0%) 0 (0%)  
      
Surgery 3 (25%) 5 (33%) 5 (36%) 3 (27%) 0.93 
      
 Stoma 0 (0%) 1 (7%) 2 (14%) 0 (0%) 0.54 
      
SCCI c 5.0 (2.9) 5.6 (1.7) 4.9 (0.9) 5.0 (2.2) 0.90 
      
HBI d 4.8 (2.7) 4.9 (3.1) 6.0 (2.8) 5.3 (4.3) 0.90 
 
Table 3: Demographics and Baseline Values of the Study Participants. 
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 a Median (inter-quartile range) reported. b Mean (standard deviation) reported. c Figures for 
patients with ulcerative colitis and unclassified inflammatory bowel disease. d Figures for 
patients with Crohn's disease and unclassified inflammatory bowel disease. P-value ≤0.01 
indicates a statistically significant difference between the four groups. CRP: C - reactive 
protein; BMI: Body Mass Index; CD: Crohn’s disease; UC: Ulcerative Colitis; IBD: Inflammatory 
Bowel Disease; SCCI: Simple Clinical Colitis Index; HBI: Harvey Bradshaw Index. 
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Variable Interaction 
e 
Exercise Advice (n=26) Omega-3 Fish Oils (n=25) 
 p-value Mean (95% CI) p-value Mean (95% CI) p-value 
FACIT-F 0.24 1.8 (-2.3, 5.8) 0.38 -4.6 (-8.6, -0.7) 0.02  
      
SCCI a 0.13 -0.6 (-1.8, 0.7) 0.37 -0.4 (-1.6, 0.9) 0.54 
HBI b 0.77 -2.0 (-4.2, 0.2) 0.07 1.1 (-1.1, 3.3) 0.31 
      
≥ 1 day’s 
capsules missed c 
0.30 0.70 (0.17, 2.96) 0.63 2.17 (0.52, 9.00) 0.29 
      
Mean MVPA/day 0.80 -7.5 (-22.6, 7.6) 0.32 -9.9 (-25.1, 5.3) 0.20 
CPM 0.78 57 (-153, 39) 0.24 -46 (-142, 51) 0.35 
Steps/day 0.71 -443 (-2829, 
1942) 
0.71 -1212 (-3600, 1176) 0.31 
Wear time/day 0.14 -0.8 (-3.1, 1.4) 0.46 0.0 (-2.3, 2.3) 0.97 
Calendar days 0.47 -0.8 (-2.0, 0.4) 0.17 -0.2 (-1.4, 0.9) 0.71 
      
Hemoglobin 0.04  -0.1 (-0.5, 0.3) 0.63 0.0 (-0.4, 0.4) 0.93 
CRP d 0.47 0.76 (0.48, 1.20) 0.24 0.95 (0.59, 1.51) 0.81 
Weight (kg) 0.76 0.3 (-1.1, 1.7) 0.69 -0.3 (-1.8, 1.1) 0.64 
      
IBD-F Section I 0.48 -2.0 (-3.8, -0.2) 0.03  0.7 (-1.1, 2.5) 0.42 
IBD-F Section II 0.33 -3.8 (-10.4, 2.7) 0.25 6.0 (-0.4, 12.3) 0.07 
      
MFI general 0.53 -1.5 (-3.1, 0.1) 0.07 0.1 (-1.5, 1.7) 0.92 
MFI physical 0.50 -0.9 (-2.6, 0.8) 0.30 1.1 (-0.5, 2.8) 0.18 
MFI activity 0.70 -0.7 (-2.6, 1.3) 0.50 1.1 (-0.8, 3.0) 0.26 
MFI motivation 0.35 -0.9 (-2.6, 0.8) 0.30 0.9 (-0.8, 2.6) 0.30 
MFI mental 0.27 -0.60 (-2.4, 1.2) 0.50 -0.38 (-2.2, 1.4) 0.67 
      
IBD-Q 0.83 3 (-7, 14) 0.56 2 (-9, 12) 0.74 
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HADS Anxiety 0.29 0.0 (-1.5, 1.6) 0.97 0.9 (-0.6, 2.4) 0.23 
HADS Depression 0.55 0.1 (-1.3, 1.5) 0.86 1.0 (-0.4, 2.4) 0.16 
 
Table 4: Comparisons of the effects of exercise advice and fish oil capsules compared with 
no exercise advice and placebo capsules respectively, on physical activity and fatigue 
assessments in patients with Inflammatory Bowel Disease.  
a Figures for patients with UC and unclassified IBD; b Figures for patients with Crohn's disease 
and unclassified inflammatory bowel disease; c Odds Ratio (95% CI) reported; d Variable 
analyzed on log scale. Ratio (95% CI) reported;  e  Indicates whether the effects of exercise 
advice are independent from those of omega-3 fish oils.  For all outcomes, p≤0.01 indicates a 
statistically significant difference between groups.  Differences were adjusted for baseline 
differences between groups.  FACIT-F: Functional Assessment of Chronic Illness Therapy – 
Fatigue scale; SCCI: Simple Clinical Colitis Index; HBI: Harvey Bradshaw Index; MVPA: 
Moderate-vigorous physical activity; CPM: Counts per minute; CRP: C - reactive protein; IBD-
F: Inflammatory Bowel Disease-Fatigue scale; MFI: Multidimensional Fatigue Inventory scale; 
IBD-Q: Inflammatory Bowel Disease – Quality of Life scale; HADS: Hospital Anxiety and 
Depression Scale. 
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FIGURES LEGENDS 
 
Figure 1: Study Outline and Schedule 
FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue scale; IBD-F: 
Inflammatory Bowel Disease - Fatigue scale; MFI: Multidimensional Fatigue Inventory scale; 
IBD-Q: Inflammatory Bowel Disease - Quality of Life scale; HADS: Hospital Anxiety and 
Depression Scale. 
Figure 2: CONSORT Flowchart for Patients in Inflammatory Bowel Disease and Fatigue Study 
Figure 3: Adverse Effects Reported during 12-week Intervention of Advice to Increase 
Physical Activity and/or Omega-3 Fatty Acids.  IBD: inflammatory bowel disease. 
 
 
 
